quoinpharma.com Open in urlscan Pro
34.68.31.156  Public Scan

Form analysis
1 forms found in the DOM

GET https://quoinpharma.com/

<form role="search" method="get" class="et-search-form" action="https://quoinpharma.com/">
  <input type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:">
</form>

Text Content

 * About
   * Company
   * Team
 * Pipeline
   * Overview
   * QRX003
   * QRX004
   * QRX007
   * QRX008
 * Investors
 * Partners
 * Contact

Select Page
 * About
   * Company
   * Team
 * Pipeline
   * Overview
   * QRX003
   * QRX004
   * QRX007
   * QRX008
 * Investors
 * Partners
 * Contact




RARE DISEASES ARE ONLY RARE IF YOU DON’T LIVE WITH ONE.

There are over 6,000 rare diseases and more than 300 million patients suffering
from those conditions.

Quoin Pharmaceuticals is an emerging specialty pharmaceutical company focused on
the development and commercialization of therapeutic products for rare and
orphan diseases.

About Us




TEAM

Quoin’s executive management and board members are highly experienced business
leaders with a track record of successful development and commercialization of
therapeutic products for previously unmet medical needs.


PIPELINE

Quoin has an innovative pipeline of development stage products that will address
unmet needs for a number of rare and orphan diseases.


INVESTORS

View our latest news, download presentations, and sign up for alerts to stay up
to date on Quoin Pharmaceuticals. 

 * Company
 * Pipeline
 * Investors
 * Partners
 * Contact

 * Follow
 * Follow

2022 ©Quoin Pharmaceuticals
Privacy Policy


MICHAEL SEMBER

Director

In his 40-year career, Mr. Sember has been COO or CEO of five diverse
pharmaceutical companies ranging from drug discovery tool providers, to
therapeutically-focused biotechnology companies, to medical devices. For
example, at Marion Laboratories (later Marion Merrell Dow) Mr. Sember handled
roles including sales, research and R&D program management. As Executive VP of
Business Development for Élan Corporation, he was responsible for strategic
collaborations, mergers and acquisitions. Mr. Sember has consulted for numerous
companies and has extensive public and private board experience. Currently Mr.
Sember serves as Chair of the Screening Panel and Board member for the
number-one-ranked Desert Angels, a Tucson, AZ-based group of angel investors.


DR. MICHAEL MYERS

Co-Founder Quoin Pharmaceuticals, Inc., Chairman, Chief Executive Officer and
Director

Dr. Myers has more than 30 years of industry experience in the drug delivery and
specialty pharmaceutical sectors. He has served CEO of Innocoll, Inc. and was
responsible for taking that company public in 2014. He has also served as
president of the drug delivery division of West Pharmaceutical Services,
president of pharmaceutical operations for Fuisz Technologies (Biovail) and has
held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers
earned his Ph.D. in Chemistry from the University College Cork. Dr. Myers serves
on the Board of Directors of Sonoran Biosciences as well as on the Advisory
Boards for two Penn State startup companies, Cranial Devices and Gradient T.


DENISE CARTER

Co-Founder Quoin Pharmaceuticals, Inc., Chief Operating Officer and Director

Ms. Denise Carter has over 30 years of experience in the drug delivery and
specialty pharmaceutical industries. Prior to Quoin, Ms. Carter was executive
vice president of business development and corporate affairs at Innocoll, Inc.,
vice president of business development of the drug delivery division of West
Pharmaceuticals, and she has held executive positions at Eurand and Fuisz
Technologies (Biovail) Ms. Carter earned her MBA from Wharton School of
Business, University of Pennsylvania and a B.S. in Chemistry from the College of
William and Mary.


GORDON DUNN

Chief Financial Officer

Gordon joined Quoin in November of 2021. He brings over 30 years of finance
experience and has served as CFO of both private and publicly traded companies.
In addition, Mr. Dunn has deep experience in investment banking and private
equity. Over the last five years he has served as Chief Financial Officer for
several private companies, most recently with Qured, a UK based healthcare
provider, from 2020 to 2021. Mr Dunn also served as CFO of Innocoll Inc. from
2012-2016. Prior to joining Innocoll, Mr. Dunn had 20 years’ experience in
investment banking and private equity, including over ten years managing the
private equity funds of NewSmith Capital, and nine years at Merrill Lynch where
he served as co-head of the European Private Equity Group and Director of Equity
Capital Markets. Mr. Dunn received a B.A. from Stanford University and a J.D.
from New York University School of Law.


DENNIS H. LANGER, MD, JD

Director

After graduating from Georgetown School of Medicine and Harvard Law School, Dr.
Langer spent over 35 years in the pharmaceutical industry at Eli Lilly, Abbott,
Searle, GSK and as President at Dr. Reddy’s, NA. He was a Director at Sirna
Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon),
Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand),
Cytogen (acquired by EUSA Pharma) and Delcath Systems. Dr. Langer is a Director
at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics. He is a
Clinical Psychiatry Professor at Georgetown and serves on the Dean’s Advisory
Board of Harvard Law School.


NATALIE LEONG

Director

Ms. Leong has worked across four continents in valuation and transactions in
sale, IPO, float, financial modeling, internal controls and raising capital. She
has experience analyzing business plans, performing market analyses, preparing
financial projections, developing valuation models, advising on equity
transactions, mergers, acquisitions and corporate restructurings. Currently, Ms.
Leong is Head of Finance for LoanStreet. Previously, she was US lead for the
Asset Liability Committee at RBC Capital Markets. At National Australia Bank,
Ms. Leong was promoted to VP of Capital Insights. She has an MBA from Wharton, a
BCom and a BA from the University of Melbourne.


JAMES CULVERWELL

Director

Currently, Mr. Culverwell is Chairman of HOX Therapeutics, focusing on prostate
cancer research. He is also NED of Safeguard Biosystems, in late stage
development of a low cost, high throughput, molecular diagnostic system.
Previously, Mr. Culverwell was NED at Atlantic Healthcare, developing treatments
for ulcerative colitis. He was NED and Chairman of Audit at Amryt
Pharmaceuticals, which focuses on rare diseases including Hypercholesterolemia
and Epidermolysis Bullosa. He was also NED at Innocoll AG. Mr. Culverwell’s
experience includes Director and Head of European Healthcare and Pharmaceutical
Equity Research at Hoare Govett/ABN Amro. And was FVP of Global Healthcare
Research at Merrill Lynch/Bank of America.


JOSEPH COOPER

Director

With 30 years of pharmaceutical industry experience, Mr. Cooper has held roles
in operational, corporate development and general management. Currently, he is
Chief of Strategy and Corporate Development at Resonea. Formerly, he was
President at Boulder Cove and Executive VP of Corporate Development at Medicis
Pharmaceutical. Earlier he was with Schein and GD Searle. His leadership
experience is in clinical research, product development, supply chain, business
development and executive management in a broad range of therapeutic areas
including dermatology, aesthetics, allergy, sleep apnea, stroke and orphan
drugs. Mr. Cooper currently serves on the board of Sonoran Biosciences,
Bioenvision and board observer for several specialty pharmaceutical companies.
He serves as a commercial partner of Tech Launch Arizona, the technology
advancement arm of the University of Arizona.


MICHAEL SEMBER

Director

In his 40-year career, Mr. Sember has been COO or CEO of five diverse
pharmaceutical companies ranging from drug discovery tool providers, to
therapeutically-focused biotechnology companies, to medical devices. For
example, at Marion Laboratories (later Marion Merrell Dow) Mr. Sember handled
roles including sales, research and R&D program management. As Executive VP of
Business Development for Élan Corporation, he was responsible for strategic
collaborations, mergers and acquisitions. Mr. Sember has consulted for numerous
companies and has extensive public and private board experience. Currently Mr.
Sember serves as Chair of the Screening Panel and Board member for the
number-one-ranked Desert Angels, a Tucson, AZ-based group of angel investors.


DR. MICHAEL MYERS

Co-Founder Quoin Pharmaceuticals, Inc., Chairman, Chief Executive Officer and
Director

Dr. Myers has more than 30 years of industry experience in the drug delivery and
specialty pharmaceutical sectors. He has served CEO of Innocoll, Inc. and was
responsible for taking that company public in 2014. He has also served as
president of the drug delivery division of West Pharmaceutical Services,
president of pharmaceutical operations for Fuisz Technologies (Biovail) and has
held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers
earned his Ph.D. in Chemistry from the University College Cork. Dr. Myers serves
on the Board of Directors of Sonoran Biosciences as well as on the Advisory
Boards for two Penn State startup companies, Cranial Devices and Gradient T.





QRX003

A once-daily topical therapy for the treatment of Netherton Syndrome (NS). In NS
patients, QRX-003 mimics the activity of the missing LEKTI protein to regulate
the shedding of skin. Read more


QRX004

Also formulated with the Invisicare technology, QRX004 is initially being
developed as a potential treatment for Recessive Dystrophic Epidermolysis
Bullosa ( RDEB).

QRX004 contains two active ingredients. The primary  ingredient induces a
read-through of nonsense mutations and leads to creation of robust and sustained
type VII collagen. The result is improved wound closure, reduced blistering and
stronger skin.


QRX006

Product content to come

By using this website, you agree to our use of cookies. We use cookies to
provide you with a great experience and to help our website run effectively.
Cookie Policy - Privacy Statement
Accept
Manage consent